Other than the effects on sVCAM-1 and sICAM-1, PCS/CFS serum similarly mediated the significantly enhanced release of IGFBP-4 in comparison to both other groups (Figure 3c). The gene discussed is IGFBP4; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.